| Chronic Obstructive Airway Disease
Bevespi Aerosphere vs Perforomist
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Bevespi Aerosphere vs Perforomist with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPerforomist has a higher rate of injection site reactions vs Bevespi Aerosphere based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Perforomist but not Bevespi Aerosphere, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Bevespi Aerosphere
Perforomist
At A Glance
Oral inhalation
Twice daily
LAMA/LABA combination
Nebulization
Twice daily
Long-acting beta2-agonist (LABA)
Indications
- Chronic Obstructive Airway Disease
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
Dosing
Chronic Obstructive Airway Disease 2 inhalations (glycopyrrolate 18 mcg and formoterol fumarate 9.6 mcg) twice daily in the morning and evening by oral inhalation; do not exceed two inhalations twice daily.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 20 mcg (one unit-dose vial) administered twice daily (morning and evening) by nebulization via standard jet nebulizer connected to an air compressor; total daily dose greater than 40 mcg is not recommended.
Contraindications
- Use of a long-acting beta2-adrenergic agonist (LABA), including formoterol fumarate, without an inhaled corticosteroid in patients with asthma
- Hypersensitivity to glycopyrrolate, formoterol fumarate, or any component of the product
- Use without an inhaled corticosteroid in patients with asthma
Adverse Reactions
Most common (>=2%) Cough, urinary tract infection
Serious Paradoxical bronchospasm, hypersensitivity reactions including anaphylaxis, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Hypersensitivity, urinary retention
Most common (>=2%) Diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, insomnia
Serious Angina, hypertension or hypotension, tachycardia, arrhythmias, hypokalemia, hyperglycemia, metabolic acidosis
Postmarketing Anaphylactic reactions, urticaria, angioedema, rash, bronchospasm
Pharmacology
BEVESPI AEROSPHERE combines glycopyrrolate, a long-acting anticholinergic (LAMA) that inhibits M3 muscarinic receptors in airway smooth muscle to produce bronchodilation, with formoterol fumarate, a long-acting selective beta2-adrenoceptor agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Long-acting beta2-adrenergic receptor agonist (LABA) that acts locally in the lung as a bronchodilator; stimulates adenyl cyclase to increase cyclic AMP levels, causing relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Bevespi Aerosphere
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (5/12) · Qty limit (9/12)
Perforomist
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (10/12)
UnitedHealthcare
Bevespi Aerosphere
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Perforomist
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (5/8)
Humana
Bevespi Aerosphere
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
Perforomist
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Bevespi Aerosphere.
No savings programs available for Perforomist.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Bevespi AerosphereView full Bevespi Aerosphere profile
PerforomistView full Perforomist profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.